AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30914493 — intervention group
Group type: COMPARATOR
Intervention: Traditional extubation
Number of subjects: 240
Study 28670249 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program based on the Precede model, conducted during four sessions twice a week for one hour.
Number of subjects: 120
Study 28670249 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program based on the Precede model
Number of subjects: 120
Study 28670249 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 120
Study 25499162 — intervention group
Group type: EXPERIMENTAL
Intervention: External trigeminal nerve stimulation (eTNS)
Number of subjects: 35
Study 25499162 — intervention group
Group type: COMPARATOR
Intervention: Control settings (crossover to effective device parameters)
Number of subjects: 35
Study 23230072 — intervention group
Group type: EXPERIMENTAL
Intervention: VascuLuminator
Number of subjects: 770
Study 23230072 — intervention group
Group type: COMPARATOR
Intervention: Control group (no VascuLuminator)
Number of subjects: 770
Study 21768737 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein (SP) formula containing 12 g of SP, given for 20 weeks
Number of subjects: 48
Study 21768737 — intervention group
Group type: COMPARATOR
Intervention: Milk protein (MP) formula, given for 20 weeks
Number of subjects: 48
Study 19537839 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubiprostone 8 microg twice daily for 3 months
Number of subjects: 193
Study 19537839 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study 19537839 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubiprostone 8 microg twice daily
Number of subjects: 193
Study 16414215 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/day isoflavone supplement (n=15)
Number of subjects: 29
Study 16414215 — intervention group
Group type: COMPARATOR
Intervention: Identical placebo capsules (n=14)
Number of subjects: 29
Study 13678386 — intervention group
Group type: EXPERIMENTAL
Intervention: Oolong tea
Number of subjects: 11
Study 13678386 — intervention group
Group type: COMPARATOR
Intervention: Green tea
Number of subjects: 11
Study 13678386 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 11
Study 10630138 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-level intervention including HIV risk reduction workshops and community HIV prevention events
Number of subjects: 690
Study 8808491 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg ascorbate per day for 4 weeks
Number of subjects: 19
Study 8808491 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 19
Study 1393763 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine, 0.28 mg to each nostril
Number of subjects: 36
Study 1393763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 31373271 — intervention group
Group type: COMPARATOR
Intervention: IV antibiotics
Number of subjects: 1054
Study 31373271 — intervention group
Group type: EXPERIMENTAL
Intervention: PO antibiotics
Number of subjects: 1054
Study 28785857 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 35
Study 28785857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 28785857 — intervention group
Group type: EXPERIMENTAL
Intervention: Age of patients (25 years or older)
Number of subjects: 35
Study 28785857 — intervention group
Group type: EXPERIMENTAL
Intervention: Onset age (younger than 24 years)
Number of subjects: 35
Study 26478187 — intervention group
Group type: COMPARATOR
Intervention: Low-GI breakfast not including fructose content (LGI)
Number of subjects: 10
Study 26478187 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-GI breakfast including fructose beverage (LGIF)
Number of subjects: 10
Study 26478187 — intervention group
Group type: EXPERIMENTAL
Intervention: High-GI breakfast (HGI)
Number of subjects: 10
Study 24518163 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable-flow nasal CPAP (nCPAP)
Number of subjects: 29
Study 24518163 — intervention group
Group type: EXPERIMENTAL
Intervention: Bubble CPAP (bCPAP) at pressures of 5, 7, and 9 cmH2O
Number of subjects: 29
Study 24518163 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal bi-level positive airway pressure (nBiPAP) at pressures of 5, 7/5, and 9/5 cmH2O
Number of subjects: 29
Study 24518163 — intervention group
Group type: COMPARATOR
Intervention: Unsupported breathing
Number of subjects: 29
Study 24518163 — intervention group
Group type: EXPERIMENTAL
Intervention: nCPAP
Number of subjects: 29
Study 21519882 — intervention group
Group type: EXPERIMENTAL
Intervention: Panoramic radiography
Number of subjects: 183474
Study 21519882 — intervention group
Group type: COMPARATOR
Intervention: CBCT
Number of subjects: 183474
Study 20488837 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity designs in randomized clinical trials
Number of subjects: 0
Study 20488837 — intervention group
Group type: EXPERIMENTAL
Intervention: Varying randomization methods, duration of follow-up, and use of surrogate endpoints
Number of subjects: 0
Study 20488837 — intervention group
Group type: COMPARATOR
Intervention: Identical protocols across centres
Number of subjects: 0
Study 20488837 — intervention group
Group type: EXPERIMENTAL
Intervention: Significant results found with varied designs
Number of subjects: 0
Study 17279849 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance of dependence by close relationship partner
Number of subjects: 0
Study 17279849 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental partner assistance during individual laboratory task
Number of subjects: 0
Study 17279849 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior assessments of dependency acceptance
Number of subjects: 0
Study 15629215 — intervention group
Group type: EXPERIMENTAL
Intervention: Fragile X premutation males
Number of subjects: 0
Study 15629215 — intervention group
Group type: COMPARATOR
Intervention: CGG repeat length
Number of subjects: 0
Study 12131220 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine (one or two doses)
Number of subjects: 66
Study 12131220 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysaccharide vaccine (one dose)
Number of subjects: 66
Study 12131220 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of pneumococcal conjugate and polysaccharide vaccines (one dose of each)
Number of subjects: 66
Study 12131220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 9607049 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP and DT
Number of subjects: 0
Study 9607049 — intervention group
Group type: COMPARATOR
Intervention: DTPwc
Number of subjects: 0
Study 9607049 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection in the buttock
Number of subjects: 0
Study 9607049 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous administration of OPV and/or HBV
Number of subjects: 0
Study 7618425 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. ketorolac tromethamine 30 mg
Number of subjects: 60
Study 7618425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 2151275 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoladex plus flutamide (Zoladex 3.6 mg every 4 weeks, flutamide 250 mg t.i.d.)
Number of subjects: 262
Study 2151275 — intervention group
Group type: COMPARATOR
Intervention: Orchidectomy
Number of subjects: 262
Study 2151275 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoladex plus flutamide
Number of subjects: 262
Study 638824 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfathesin
Number of subjects: 54
Study 638824 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 54
Study 638824 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfathesin and Thiopentone
Number of subjects: 54
Study 31908178 — intervention group
Group type: EXPERIMENTAL
Intervention: PAT removal (group A, n = 90)
Number of subjects: 181
Study 31908178 — intervention group
Group type: COMPARATOR
Intervention: PAT retention (group B, n = 91)
Number of subjects: 181
Study 30122130 — intervention group
Group type: EXPERIMENTAL
Intervention: Vectorcardiographic beat‐to‐beat variability parameters in patients with pAF during sinus rhythm
Number of subjects: 229
Study 30122130 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate independent parameters in patients with pAF during sinus rhythm
Number of subjects: 229
Study 30122130 — intervention group
Group type: COMPARATOR
Intervention: Control group (no history of AF)
Number of subjects: 229
Study 26360494 — intervention group
Group type: EXPERIMENTAL
Intervention: Girl's education
Number of subjects: 364
Study 26360494 — intervention group
Group type: COMPARATOR
Intervention: Mother's education
Number of subjects: 364
Study 26360494 — intervention group
Group type: COMPARATOR
Intervention: No-intervention
Number of subjects: 364
Study 25434967 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-hormone artificial pancreas
Number of subjects: 0
Study 25434967 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-hormone artificial pancreas
Number of subjects: 0
Study 25434967 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin pump therapy
Number of subjects: 0
Study 23340533 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine (50 mg)
Number of subjects: 40
Study 23340533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 21292803 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise/movement optimization intervention (12-week home-based program of shoulder strengthening and stretching exercises)
Number of subjects: 80
Study 21292803 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise/movement optimization intervention
Number of subjects: 80
Study 21292803 — intervention group
Group type: COMPARATOR
Intervention: Attention control group (1-hour educational video)
Number of subjects: 80
Study 21292803 — intervention group
Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 80
Study 19059635 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body hyperthermia (WBH) in combination with carboplatin
Number of subjects: 47
Study 16919060 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive advice to withdraw the overused medication (Group A)
Number of subjects: 120
Study 16919060 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard out‐patient detoxification programme (advice+prednisone+preventive treatment) (Group B)
Number of subjects: 120
Study 16919060 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard in‐patient withdrawal programme (Group C)
Number of subjects: 120
Study 16919060 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 120
Study 15230949 — intervention group
Group type: EXPERIMENTAL
Intervention: rFVIIa 90 micrograms kg(‐1)
Number of subjects: 12
Study 15230949 — intervention group
Group type: EXPERIMENTAL
Intervention: rFVIIa 180 micrograms kg(‐1)
Number of subjects: 12
Study 11164700 — intervention group
Group type: EXPERIMENTAL
Intervention: Rufinamide (400-1600 mg/day)
Number of subjects: 50
Study 11164700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 11164700 — intervention group
Group type: EXPERIMENTAL
Intervention: Rufinamide
Number of subjects: 50
Study 9245470 — intervention group
Group type: EXPERIMENTAL
Intervention: Holistic cue integration mechanism
Number of subjects: 0
Study 9245470 — intervention group
Group type: EXPERIMENTAL
Intervention: Intersection cuing mechanism
Number of subjects: 0
Study 9245470 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent cuing mechanism
Number of subjects: 0
Study 9245470 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound cue model
Number of subjects: 0
Study 8270721 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency flow interrupted ventilation (HFFIV)
Number of subjects: 24
Study 8270721 — intervention group
Group type: COMPARATOR
Intervention: Conventional mechanical ventilation (CMV)
Number of subjects: 24
Study 2826550 — intervention group
Group type: EXPERIMENTAL
Intervention: IV enalaprilat 1.25 mg q6h for 24 hours, increased to 5 mg q6h for nonresponding patients
Number of subjects: 14
Study 2826550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 31363946 — intervention group
Group type: EXPERIMENTAL
Intervention: Second Step SEL program
Number of subjects: 0
Study 31363946 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 29562147 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication therapy with antibiotics
Number of subjects: 396
Study 29562147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 396
Study 26522058 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI plus CT guided (125)I-seed implantation (CTII)
Number of subjects: 57
Study 26522058 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI alone
Number of subjects: 57
Study 25403867 — intervention group
Group type: EXPERIMENTAL
Intervention: Chia flour (35 g/day) for 12 weeks
Number of subjects: 26
Study 25403867 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 22362420 — intervention group
Group type: EXPERIMENTAL
Intervention: Double pass PDL (11 J/cm², second pass 6 minutes after the first pass)
Number of subjects: 17
Study 22362420 — intervention group
Group type: COMPARATOR
Intervention: Single pass PDL (12 J/cm²)
Number of subjects: 17
Study 19590523 — intervention group
Group type: EXPERIMENTAL
Intervention: Excimer laser trabeculotomy (ELT)
Number of subjects: 30
Study 19590523 — intervention group
Group type: COMPARATOR
Intervention: Selective laser trabeculoplasty (SLT)
Number of subjects: 30
Study 17623738 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary fatigue management programme (MFMP)
Number of subjects: 51
Study 17623738 — intervention group
Group type: COMPARATOR
Intervention: Placebo intervention programme
Number of subjects: 51
Study 17623738 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 51
Study 15751370 — intervention group
Group type: EXPERIMENTAL
Intervention: Total joint replacement surgery (hip or knee)
Number of subjects: 100
Study 11934185 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 percent penciclovir cream
Number of subjects: 4573
Study 11934185 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 4573
Study 10860034 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline fiber therapy
Number of subjects: 17
Study 10860034 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 17
Study 8649265 — intervention group
Group type: EXPERIMENTAL
Intervention: SPf66 vaccine
Number of subjects: 100
Study 8649265 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vaccine)
Number of subjects: 100
Study 1973351 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Skills Training (SST) - 25 twice a week 90-min group sessions
Number of subjects: 78
Study 1973351 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Exposure (GE) - 4 weekly sessions (8-hr total, including 2 hr discussion)
Number of subjects: 78
Study 1973351 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Exposure (IE) - 4 weekly sessions (3 hr total, including 1 hr discussion)
Number of subjects: 78
Study 1973351 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 78
Study 1973351 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Exposure (GE) within skills deficits subgroup
Number of subjects: 78
Study 41229 — intervention group
Group type: EXPERIMENTAL
Intervention: Tienilic acid 250 mg
Number of subjects: 0
Study 41229 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide 50 mg
Number of subjects: 0
Study 30365247 — intervention group
Group type: EXPERIMENTAL
Intervention: Penimaster PRO group (PG)
Number of subjects: 93
Study 30365247 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention group (NIG)
Number of subjects: 93
Study 28812321 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg daily (Group B)
Number of subjects: 100
Study 28812321 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 20 mg daily (Group A)
Number of subjects: 100
Study 28812321 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 26596056 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran (110 mg b.i.d)
Number of subjects: 280
Study 26596056 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban (5 mg b.i.d)
Number of subjects: 280
Study 26596056 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (20 mg once daily)
Number of subjects: 280
Study 26596056 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 280
Study 24002093 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 203
Study 24002093 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quintile of plasma tenofovir concentrations
Number of subjects: 203
Study 24002093 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quintile of intracellular tenofovir diphosphate concentration
Number of subjects: 203
Study 24002093 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plasma tenofovir concentrations
Number of subjects: 203
Study 24002093 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intracellular tenofovir diphosphate
Number of subjects: 203
Study 20680696 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiocolloid combined with methylene dye localization (RCML)
Number of subjects: 157
Study 20680696 — intervention group
Group type: COMPARATOR
Intervention: Wire localization (WL)
Number of subjects: 157
Study 19747876 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone-based protocol (DCOG ALL-9) for NHR patients: three-drug induction (dexamethasone, vincristine, asparaginase) for 6 weeks, medium-dose methotrexate for 3 weeks, maintenance therapy until 109 weeks.
Number of subjects: 859
Study 19747876 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone-based protocol (DCOG ALL-9) for HR patients: four-drug induction (as for NHR plus daunorubicin) for 6 weeks, high-dose methotrexate for 8 weeks, maintenance therapy until 109 weeks.
Number of subjects: 859
Study 19747876 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall results of the DCOG ALL-9 protocol for all patients.
Number of subjects: 859
Study 19747876 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall results of the DCOG ALL-9 protocol for NHR patients.
Number of subjects: 859
Study 19747876 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall results of the DCOG ALL-9 protocol for HR patients.
Number of subjects: 859
Study 19747876 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall results of the DCOG ALL-9 protocol regarding isolated CNS relapses.
Number of subjects: 859
Study 19747876 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analysis of prognostic factors.
Number of subjects: 859
Study 17978321 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent preventive intervention for disruptive boys
Number of subjects: 250
Study 17978321 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 250
Study 15530214 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Training (PT)
Number of subjects: 89
Study 15530214 — intervention group
Group type: COMPARATOR
Intervention: Waiting List Control (WLC)
Number of subjects: 89
Study 11455770 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms PGE1 + 15 mg papaverine hydrochloride + 0.5 mg phentolamine (trimix)
Number of subjects: 91
Study 11455770 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg papaverine hydrochloride + 1 mg phentolamine (bimix)
Number of subjects: 91
Study 11455770 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micrograms PGE1
Number of subjects: 91
Study 9926882 — intervention group
Group type: EXPERIMENTAL
Intervention: Joel-Cohen incision with nonclosure of pelvic and parietal peritoneum (group 1)
Number of subjects: 299
Study 9926882 — intervention group
Group type: COMPARATOR
Intervention: Pfannenstiel incision with peritonealization (group 2)
Number of subjects: 299
Study 9926882 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 299
Study 7803722 — intervention group
Group type: EXPERIMENTAL
Intervention: AZT combined with poly(I):poly(C12U)
Number of subjects: 11
Study 7803722 — intervention group
Group type: COMPARATOR
Intervention: AZT alone
Number of subjects: 11
Study 3055036 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mmol/kg gadolinium diethylenetriaminepentaacetic acid (Gd‐DTPA)
Number of subjects: 20
Study 3055036 — intervention group
Group type: COMPARATOR
Intervention: No Gd‐DTPA (control group)
Number of subjects: 20
Study 29175149 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine plus pertuzumab
Number of subjects: 444
Study 29175149 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel, carboplatin, and trastuzumab plus pertuzumab
Number of subjects: 444
Study 28526536 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine (3·6 mg/kg intravenously every 3 weeks)
Number of subjects: 991
Study 28526536 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine (1000 mg/m2 orally twice daily on days 1‐14 of each 21-day cycle) plus Lapatinib (1250 mg orally once daily on days 1‐21)
Number of subjects: 991
Study 28526536 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine
Number of subjects: 991
Study 28526536 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine plus Lapatinib (control)
Number of subjects: 991
Study 26143520 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized video feedback (IVF)
Number of subjects: 0
Study 26143520 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced unsupervised video feedback (UVF)
Number of subjects: 0
Study 26143520 — intervention group
Group type: COMPARATOR
Intervention: Standard lecture feedback (SLF)
Number of subjects: 0
Study 23250671 — intervention group
Group type: EXPERIMENTAL
Intervention: Angled-tipped guidewire (AGW)
Number of subjects: 155
Study 23250671 — intervention group
Group type: COMPARATOR
Intervention: Straight-tipped guidewire (SGW)
Number of subjects: 155
Study 21990410 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg twice daily
Number of subjects: 561
Study 21990410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 561